A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia
← catalyst calendarNCT06980428 · readout in 107 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
136estimated
Sites
6
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-27 | actual | When the study began enrolling |
| Primary completion | 2026-12-04 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-04 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Healthy Participants
- Dyslipidemia
Interventions
- Drug: AZD4954
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPart A: Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
measured From Screening (Day -28 to Day -2) to Follow-up visit (Up to Day 29±2 days)
Part B: Number of participants with AEs and SAEs
measured From Screening (Day -28 to Day -2) to Follow-up visit (Up to Day 49±2 days)
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed